|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-5-2
|
|
pubmed:abstractText |
The cancer-testis antigen NY-ESO-1 is expressed by >40% of advanced epithelial ovarian cancers and is a promising immunotherapeutic target. In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/CTAG1B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Mannitol,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Oleic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/montanide ISA 51
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AghajanianCarolC,
pubmed-author:DiefenbachCatherine S MCS,
pubmed-author:DupontBoB,
pubmed-author:DupontJakobJ,
pubmed-author:GnjaticSachaS,
pubmed-author:HensleyMartee LML,
pubmed-author:IasonosAlexiaA,
pubmed-author:JungbluthAchim AAA,
pubmed-author:LeeHelenH,
pubmed-author:OldLloyd JLJ,
pubmed-author:PezzulliSandraS,
pubmed-author:SabbatiniPaulP,
pubmed-author:SpriggsDavid RDR
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2740-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18451240-Adult,
pubmed-meshheading:18451240-Aged,
pubmed-meshheading:18451240-Antigens, Neoplasm,
pubmed-meshheading:18451240-CD8-Positive T-Lymphocytes,
pubmed-meshheading:18451240-Cancer Vaccines,
pubmed-meshheading:18451240-Female,
pubmed-meshheading:18451240-HLA-A Antigens,
pubmed-meshheading:18451240-Humans,
pubmed-meshheading:18451240-Mannitol,
pubmed-meshheading:18451240-Membrane Proteins,
pubmed-meshheading:18451240-Middle Aged,
pubmed-meshheading:18451240-Oleic Acids,
pubmed-meshheading:18451240-Ovarian Neoplasms,
pubmed-meshheading:18451240-Peptide Fragments
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center,New York, New York 10021, USA. magicdc@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
